ArticleNature biotechnology2026
A multiobjective AI model for LNP engineering enhances tissue-selective mRNA delivery.
Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From serendipity to rational design: Accelerating ionizable lipid discovery with LipidAI.Acta pharmaceutica Sinica. B · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Lipid nanoparticle (LNP) delivery of RNA therapeutics is constrained by poor tissue selectivity and off-target toxicity. Most high-throughput screening approaches have focused on single-target efficacy while overlooking off-target uptake. Here we report multiobjective LNP engineering with artificial intelligence (MOLEA), a system that integrates high-dimensional lipid representations, cell-type-resolved transfection data and multitask optimization to design ionizable lipids with both high potency and biological selectivity. MOLEA learns structure-function relationships across diverse cellular contexts to identify lipids that preferentially deliver mRNA to target tissue while minimizing hepatocyte transfection. Applying MOLEA to cartilage, we developed K9 LNPs, which achieve >90% transfection efficiency in mouse joint chondrocytes and a 13.5-fold increase in knee-to-liver selectivity compared to the clinical benchmark SM-102. We demonstrate chondrocyte-specific Mmp13 editing in osteoarthritis mouse models, leading to sustained cartilage protection and suppression of disease-associated immune and matrix remodeling. Our findings demonstrate how artificial-intelligence-guided multiobjective optimization can enable precision RNA delivery with potential applications to other tissues.
Identifiers
42050330What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.